Supernus Pharmaceuticals, Inc. × Epilepsy
Supernus Pharmaceuticals, Inc. epilepsy: 3 indexed trials, 1 recruiting studies across 2 countries in the current NeuroRisk corpus.
Request comparative brief →Indexed trials3
Recruiting1
Countries2
Indexed studies
NCT00918424Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects
United StatesAPPROVED_FOR_MARKETING
United StatesAPPROVED_FOR_MARKETING
NCT05518578Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
United StatesPHASE2
United StatesPHASE2
NCT03156439Bioavailability, Safety, and Tolerability of BIS-001 ER
AustraliaPHASE1
AustraliaPHASE1
Enterprise comparison
Compare sponsor momentum, recruiting activity, geography and connected evidence with the broader NeuroRisk intelligence layer.
Request enterprise access →